Paratek Pharmaceuticals Stock Current Valuation
Valuation analysis of Paratek Pharmaceuticals helps investors to measure Paratek Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Paratek Pharmaceuticals Company Current Valuation Analysis
Paratek Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Paratek Pharmaceuticals Current Valuation | 345.3 M |
Most of Paratek Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Paratek Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Paratek Pharmaceuticals has a Current Valuation of 345.3 M. This is 97.6% lower than that of the Pharmaceuticals sector and 92.57% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.92% higher than that of the company.
Paratek Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Paratek Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics of similar companies.Paratek Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Paratek Fundamentals
Return On Asset | -0.18 | |||
Profit Margin | (0.35) % | |||
Operating Margin | (0.25) % | |||
Current Valuation | 345.3 M | |||
Shares Outstanding | 57.32 M | |||
Shares Owned By Insiders | 11.70 % | |||
Shares Owned By Institutions | 55.08 % | |||
Number Of Shares Shorted | 2.64 M | |||
Price To Earning | (5.49) X | |||
Price To Sales | 0.86 X | |||
Revenue | 150.79 M | |||
Gross Profit | 99.39 M | |||
EBITDA | (44.9 M) | |||
Net Income | (63.57 M) | |||
Cash And Equivalents | 57.01 M | |||
Cash Per Share | 1.03 X | |||
Total Debt | 258.41 M | |||
Debt To Equity | 3.20 % | |||
Current Ratio | 3.11 X | |||
Book Value Per Share | (3.52) X | |||
Cash Flow From Operations | (66.14 M) | |||
Short Ratio | 6.74 X | |||
Earnings Per Share | (1.11) X | |||
Price To Earnings To Growth | (0.02) X | |||
Target Price | 3.1 | |||
Number Of Employees | 268 | |||
Beta | 1.7 | |||
Market Capitalization | 127.83 M | |||
Total Asset | 172.54 M | |||
Retained Earnings | (930.45 M) | |||
Working Capital | 99.45 M | |||
Current Asset | 127.46 M | |||
Current Liabilities | 21.75 M | |||
Z Score | -6.55 | |||
Net Asset | 172.54 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance |